Literature DB >> 36125732

The impact of the metabolic score for insulin resistance on cardiovascular disease: a 10-year follow-up cohort study.

Z Wu1, H Cui1, Y Zhang1, L Liu1, W Zhang1, W Xiong1, F Lu2, J Peng3, J Yang4.   

Abstract

PURPOSE: To investigate whether the metabolic score for insulin resistance (METS-IR) is associated with an increased risk of cardiovascular disease (CVD).
METHODS: A total of 6489 participants aged 35-70 years without a history of CVD were included in this prospective cohort study. The median follow-up time was 10.6 years. The METS-IR was calculated as ln [2 × FPG (mg/dL) + fasting TG (mg/dL)] × BMI (kg/m2)/ln [HDL-C (mg/dL)]. The primary outcome was CVD, defined as the composite of coronary heart disease (CHD) and stroke.
RESULTS: During follow-up, 396 individuals developed CVD. Kaplan-Meier survival curves by quintiles of METS-IR showed statistically significant differences (log-rank test, P < 0.001). Multivariate Cox regression analysis showed that the hazard ratio [95% confidence interval (95% CI)] of CVD was 1.80 (1.24-2.61) in quintile 5 and 1.17 (1.05-1.31) for per standard deviation (SD) increase in METS-IR. In subgroup analysis, the significant association between METS-IR and CVD was mainly observed among females and subjects without diabetes mellitus. A significant interaction was found between gender and METS-IR (P-interaction = 0.001). Moreover, adding METS-IR to models with traditional risk factors yielded a significant improvement in discrimination and reclassification of incident CVD.
CONCLUSION: The elevated METS-IR was independently associated with incident CVD, suggesting that the METS-IR might be a valuable indicator for risk stratification and early intervention of CVD.
© 2022. The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE).

Entities:  

Keywords:  Cardiovascular disease; Coronary heart disease; Insulin resistance; The metabolic score for insulin resistance

Year:  2022        PMID: 36125732     DOI: 10.1007/s40618-022-01925-0

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   5.467


  25 in total

1.  Atherosclerosis: Pathophysiology of insulin resistance, hyperglycemia, hyperlipidemia, and inflammation.

Authors:  Joshua K Beverly; Matthew J Budoff
Journal:  J Diabetes       Date:  2019-08-14       Impact factor: 4.006

Review 2.  Inflammation and metabolic dysfunction: links to cardiovascular diseases.

Authors:  Annika Taube; Raphaela Schlich; Henrike Sell; Kristin Eckardt; Juergen Eckel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-23       Impact factor: 4.733

Review 3.  Insulin resistance, hyperglycemia, and atherosclerosis.

Authors:  Karin E Bornfeldt; Ira Tabas
Journal:  Cell Metab       Date:  2011-11-02       Impact factor: 27.287

4.  The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond.

Authors:  George A Mensah; Gregory A Roth; Valentin Fuster
Journal:  J Am Coll Cardiol       Date:  2019-11-19       Impact factor: 24.094

5.  METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes.

Authors:  Omar Yaxmehen Bello-Chavolla; Paloma Almeda-Valdes; Donaji Gomez-Velasco; Tannia Viveros-Ruiz; Ivette Cruz-Bautista; Alonso Romo-Romo; Daniel Sánchez-Lázaro; Dushan Meza-Oviedo; Arsenio Vargas-Vázquez; Olimpia Arellano Campos; Magdalena Del Rocío Sevilla-González; Alexandro J Martagón; Liliana Muñoz Hernández; Roopa Mehta; César Rodolfo Caballeros-Barragán; Carlos A Aguilar-Salinas
Journal:  Eur J Endocrinol       Date:  2018-03-13       Impact factor: 6.664

6.  Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association.

Authors:  Salim S Virani; Alvaro Alonso; Emelia J Benjamin; Marcio S Bittencourt; Clifton W Callaway; April P Carson; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Francesca N Delling; Luc Djousse; Mitchell S V Elkind; Jane F Ferguson; Myriam Fornage; Sadiya S Khan; Brett M Kissela; Kristen L Knutson; Tak W Kwan; Daniel T Lackland; Tené T Lewis; Judith H Lichtman; Chris T Longenecker; Matthew Shane Loop; Pamela L Lutsey; Seth S Martin; Kunihiro Matsushita; Andrew E Moran; Michael E Mussolino; Amanda Marma Perak; Wayne D Rosamond; Gregory A Roth; Uchechukwu K A Sampson; Gary M Satou; Emily B Schroeder; Svati H Shah; Christina M Shay; Nicole L Spartano; Andrew Stokes; David L Tirschwell; Lisa B VanWagner; Connie W Tsao
Journal:  Circulation       Date:  2020-01-29       Impact factor: 29.690

7.  Global Burden of Disease Study 2019 suggests that metabolic risk factors are the leading drivers of the burden of ischemic heart disease.

Authors:  Wenxin Wang; Manli Hu; Hui Liu; Xingyuan Zhang; Haomiao Li; Feng Zhou; Ye-Mao Liu; Fang Lei; Juan-Juan Qin; Yan-Ci Zhao; Ze Chen; Weifang Liu; Xiaohui Song; Xuewei Huang; Lihua Zhu; Yan-Xiao Ji; Peng Zhang; Xiao-Jing Zhang; Zhi-Gang She; Juan Yang; Hailong Yang; Jingjing Cai; Hongliang Li
Journal:  Cell Metab       Date:  2021-09-02       Impact factor: 27.287

8.  Dose-Response Associations of Metabolic Score for Insulin Resistance Index with Nonalcoholic Fatty Liver Disease among a Nonobese Chinese Population: Retrospective Evidence from a Population-Based Cohort Study.

Authors:  Xintian Cai; Jing Gao; Junli Hu; Wen Wen; Qing Zhu; Mengru Wang; Shasha Liu; Jing Hong; Ting Wu; Shunfan Yang; Guzailinuer Tuerxun; Nanfang Li
Journal:  Dis Markers       Date:  2022-02-23       Impact factor: 3.434

9.  The Effect of Intravenous Dexamethasone and Dexmedetomidine on Analgesia Duration of Supraclavicular Brachial Plexus Block: A Randomized, Four-Arm, Triple-Blinded, Placebo-Controlled Trial.

Authors:  Boohwi Hong; Chahyun Oh; Yumin Jo; Woosuk Chung; Eunhye Park; Hanmi Park; Seokhwa Yoon
Journal:  J Pers Med       Date:  2021-12-01

10.  Insulin resistance surrogates predict hypertension plus hyperuricemia.

Authors:  Yaxin Li; Aijun You; Brian Tomlinson; Longfei Yue; Kanjie Zhao; Huimin Fan; Liang Zheng
Journal:  J Diabetes Investig       Date:  2021-06-06       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.